Search

Displaying results 4521 - 4530 of 7063 in total
  1. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    [L48681] Toripalimab is a selective, recombinant, humanized IgG4 monoclonal antibody targeted against the PD-1 receptor. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

  2. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  3. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its … Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.

  4. Drug

    Benzonatate

    go.drugbank.com/drugs/DB00868
    Approved

    Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles. … [A5790] Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug.

    Products: D-TATO
  5. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]

  6. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.

    Synonyms: D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-
  7. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    cell morphology and a risk for transformation to acute myeloid leukemia. … Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase.

  8. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … [A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells

  9. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  10. Drug

    Cyclo(prolylglycyl)

    go.drugbank.com/drugs/DB04541
    Investigational

    NA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy

    Synonyms: (S)-Hexahydropyrrolo(1,2-a)pyrazine-1,4-dione-4-17O